Severe and Symptomatic Calcium Disorders Caused by Secondary Bone Disease in a Patient with a Thyroid Storm by Woittiez, Lycke Renate et al.
Doi: 10.12890/2014_000117          European Journal of Case Reports in Internal Medicine 
                                                                          © EFIM 2014
Received: 30/07/2014 
Accepted: 17/09/2014
Published: 14/10/2014
How to cite this article: Woittiez LR., Hendriks BJC, Wesselink EJ, Paske M, Kanen BLJ. Severe and Symptomatic Calcium Disorders Caused by 
Secondary Bone Disease in a Patient with a Thyroid Storm, EJCRIM 2014;1:doi: 10.12890/2014_000117
Conflicts of Interests: The authors declare that they have no conflicts of interest related to this research.
Severe and Symptomatic Calcium Disorders Caused by Secondary Bone Disease 
in a Patient with a Thyroid Storm
Lycke Renate Woittieza Bart Jacobus Cornelis Hendriksb, Elsbeth Johanna Wesselinkb, 
Marcel te Paskec, Boris Lambertus Johannes Kanena
a Department of Internal Medicine, Zaans Medical Centre, Zaandam, The Netherlands
b Pharmacy Department, Zaans Medical Centre, Zaandam, The Netherlands
c General Practice, Hoofddorp, The Netherlands
Abstract
A patient with Graves’ disease was admitted with a thyroid storm. She had severe hypercalcaemia caused by thyrotoxicosis. 
Treatment was complicated by vomiting and diarrhoea. With intravenous ondansetron, hydration and bisphosphonates, GI 
symptoms improved and oral thyreostatics could be started. This, combined with bisphosphonate administration, resulted 
in a mild hungry bone syndrome. 
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Introduction
Hypercalcaemia has several known causes, but primary hyperparathyroidism and malignancy-associated causes account 
for 90% [1]. 16%–23% of patients with hyperthyroidism have hypercalcaemia, but this is usually mild and asymptomatic 
[2]. A calcium concentration as high as in this case has been described only once before [3].
Treatment of a thyroid storm should be started promptly but can be difficult when patients have gastrointestinal complaints. 
Hypercalcaemia as a result of high bone turnover can aggravate gastrointestinal symptoms. Clinicians should be aware of 
the limited availability of parenteral treatment options and alternative strategies in this acute situation.
Case report
A 36-year-old woman had recently been diagnosed with Graves’ disease. Treatment was postponed because she was 
breastfeeding. She presented at the emergency department with complaints of severe diarrhoea, a fever, tremor, nausea 
and vomiting. 
Normal values On admission, 19 July 20 July 23 July 27 July 7 August
Hb (mmol/l) 7.8–9.6 7.7 7.8
MCV (fl) 80–100 81
Leukocytes (x 109/l) 4.5–10.0 9.6
Thrombocytes (x 109/l) 150–400 249
Sodium (mmol/l) 132–145 136 138
Potassium (mmol/l) 3.4–4.5 3.9 3.1 4.4
Creatinine (mmol/l) 44–80 44 43 44
Urea (mmol/l) <8.0 3.7 2.2 4.8
Calcium (mmol/l) 2.15–2.55 3.51 2.99 1.84 2.02 2.35
Phosphate (mmol/l) 0.80–1.40 0.63 1.08
Albumin (g/l) 35–52 39 30 35 40
ASAT (U/l) <30 28
ALAT (U/l) <35 47
Alkalic phosphatase (U/l) <120 100
Lactate dehydrogenase (U/l) <250 409
Amylase (U/l) <100 171 106
CRP (mg/l) <5.0 5.3 12
TSH (mlU/l) 0.30–3.7 <0.01 <0.01
fT4 (pmol/l) 12–21 >100 38 9.0
T3 (nmol/l) 1.2–2.8 4.8 1.3 1.4
PTH (pmol/l) 1.60–6.90 0.54
Vitamin D (pmol/l) 47.0–130.3 155.5
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Table 1: Laboratory values
On physical examination, we saw a thin, weak woman with a temperature of 38.6°C and a tachycardia of 114 beats/min. 
Further physical examination revealed a mildly enlarged thyroid gland but was otherwise unremarkable. There were no 
signs of Graves’ ophthalmopathy. 
The laboratory results showed a thyroid-stimulating hormone (TSH) of <0.01 mU/l, free T4 of >100 pmol/l and calcium 
level of 3.53 mmol/l (Table 1). 
She was diagnosed with a thyroid storm and a 
severe symptomatic hypercalcaemia and admitted 
to our hospital. Parathyroid hormone (PTH) was low, 
and a bone scan showed a diffuse increase in bone 
remodelling (Fig. 1).
Because of severe vomiting, we prescribed intravenous 
propylthiouracil (PTU) 200 mg q.i.d., beta blockade 
and Lugol’s solution 1 ml t.i.d. However, our hospital 
pharmacist informed us that non-oral formulations 
of thionamides are not commercially available in the 
Netherlands. Given the acute nature and severity 
of disease, compounding the medication was not a 
viable option. Figure 1:  Bone scan
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Figure 2: Levels of calcium and free T4.
We decided to treat vomiting with intravenous ondansetron 4 mg q.i.d. Hypercalcaemia was treated with hydration and 
pamidronate. Vomiting diminished and oral thionamide and Lugol’s solution could be started. Hungry bone syndrome 
was expected, and four days after admission our patient developed hypocalcaemia. We prescribed calcium and vitamin 
D, which increased the calcium to normal values (Fig. 2). Eight days after admission, the patient could be discharged in 
significantly improved condition. 
Discussion
Signs and symptoms of thyrotoxicosis are due to increased metabolic rate and include hyperactivity, irritability, palpitations, 
diarrhoea and vomiting. Without treatment, mortality of Graves’ disease is 10%–30% [1]. With treatment, the prognosis is 
good. In its most severe form, it can present as a “thyroid storm”, with a mortality of 20%–30% [4].
Symptoms of hypercalcaemia include fatigue, nausea, vomiting and cardiac arrhythmias [1]. In this case, both thyrotoxicosis 
and hypercalcaemia could cause gastrointestinal complaints. 
Thyrotoxicosis causes hypercalcaemia by an increase in both the number and activity of osteoclasts [5], and increases the 
responsiveness of osteoclasts to PTH [6]. It also causes high circulating IL-6 levels, stimulating osteoclastogenesis [7]. The 
severity of hyperthyroidism correlates positively with the rate of bone resorption [7].
Although serum calcium is often increased, net calcium balance is negative due to an increased calcium excretion [8]. 
Compensatory hypoparathyroidism and low levels of active vitamin D are usually found [7, 9]. This patient had a slightly 
elevated concentration of vitamin D, but not enough to significantly increase calcium. 
The increased bone turnover in thyrotoxicosis, shown in the bone scan in Fig. 1, causes decreased bone mineral density 
and an increased fracture risk [10].
Because thyroid storms have high mortality rates, treatment should be started without delay [11]. Prevention of synthesis 
of new T4 and T3 can be achieved by thionamides. As soon as, and only after, synthesis is suppressed, inorganic iodine 
should be given to block thyroid hormone release. Beta blockers are required to control the cardiovascular symptoms of 
the thyroid storm.
An elevated calcium level can lead to neurologic complications and cardiac arrhythmias. Treatment of thyrotoxicosis with thionamides 
is expected to lower the rate of bone turnover and therefore gradually decrease the serum calcium level in days to weeks [12]. 
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However, due to the severity of symptoms, we felt that we could not wait for this. In addition to hydration with intravenous 
fluids, we decided to treat with pamidronate because its calcium-lowering effect starts within 24 hours.
Four days after admission, hypocalcaemia developed, which we attributed to hungry bone syndrome. This condition is 
most commonly seen after parathyroidectomy [13]. When treatment for thyrotoxicosis is initiated, bone formation starts 
again, leading to an increased uptake of calcium in bone [14]. This effect was probably aggravated by the bisphosphonate. 
With replenishment of calcium and vitamin D the serum calcium levels in our patient normalized. 
Treatment of thyrotoxicosis was further complicated by vomiting, which could have been caused by both hypercalcaemia 
and thyrotoxicosis. Rectal, sublingual and intravenous preparations of both PTU and inorganic iodine have been 
compounded and used successfully in a few cases [15]. However, parenteral formulations of inorganic iodine or PTU are 
not commercially available in the Netherlands. Rectal preparations were unsuitable for use in our patient because of 
severe diarrhoea.
We successfully treated vomiting with ondansetron. To our knowledge, the effective use of ondansetron for vomiting in 
thyroid storm with hypercalcaemia has not been described before.
Conclusion
Thyrotoxicosis is a rare cause of severe symptomatic hypercalcaemia. Vomiting and diarrhoea can complicate treatment 
because parenteral formulations of thyreostatics are not commercially available in several countries, including the 
Netherlands. However, intravenous ondansetron seems efficacious in treating vomiting in thyroid storm, thus facilitating 
oral administration of thyreostatics. Hypercalcaemia in thyroid storm can be corrected by hydration, thyreostatic treatment 
and beta blockade. Especially if bone resorption is inhibited using a bisphosphonate, hungry bone syndrome must be 
anticipated and treated accordingly, since thyrotoxicosis induces a net calcium deficit.
 
Learning Points
• Thyroid storm is an endocrine emergency with high mortality which needs prompt treatment.
• Thyrotoxicosis can increase calcium levels due to several mechanisms.
• When gastrointestinal symptoms are complicating treatment, intravenous ondansetron can be used to facilitate oral 
treatment.
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